Summary
The Eastern Cooperative Oncology Group (ECOG) conducted a phase II trial of Dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in 28 patients with advanced malignant melanoma, none of whom had received prior cytotoxic chemotherapy. 27 of 28 patients were ECOG performance status 0 or 1. Mitoxantrone was administered at a dose of 12 mg/M2 as a 30–45 minute intravenous infusion repeated every 3 weeks as toxicity and response permitted. Dose limiting toxicity was myelosuppression. No cardiotoxicity was encountered in this study. In this optimal group of patients, only one partial response to Mitoxantrone was observed. At this dose and schedule, Mitoxantrone has no clinically worthwhile activity against malignant melanomas.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
The Medical Research Division, American Cyanamid Company. Clinical Brochure, Anthracenedione (CL 232, 315-NSC-301739). Bethesda, Md., Investigational Drug Branch, Cancer Therapy Evaluation Program, Division of Cancer Treatment, National Cancer Institute, March, 1979
Wallace RE, Murdock KC, Augier RB, Duff FE: Activity of a novel anthracenedione, 1,3-dihydroxy-5,8-bis (((2-((2-hydroxy-ethyl)amino))-9,10-anthracenedione dihydrochloride, against experimental tumors in mice. Cancer Res 39:1570–1574, 1979
VonHoff DD, Coltman CA Jr., Forseth B: Activity of Mitoxantrone in a Human Tumor Cloning System. Cancer Res 41:1853–1855, 1981
VonHoff DD, Polland E, Kuhn J, Murray E, Coltman CA Jr: Phase I Clinical Investigation of 1,4 dihydroxy-5,8-bis (((2-((2-hydroxyethyl)-animo (ethyl (amino))-9,10-anthracenedione dihydrochloride (NSC 301739) a new anthracenedione. Cancer Res 40:1516–1518, 1980
Aapro M, Mackel C, Alberts D, Woolfenden J: Phase II cardiotoxicity study of mitoxantrone hydrochloride using exercise radionuclide evaluation of left ventricular cardiac ejection fraction (LVEF). Proc Am Soc Clin Oncol 1:14, 1982 (Abstr.)
Coltman CA, McDaniel TM, Balcerzak SP, Morrison FS, VonHoff DD: Mitoxantrone Hydrochloride (NSC-3107939) in Lymphoma. Invest N Drugs 1:65–70, 1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arseneau, J.C., Schoenfeld, D.A. & Borden, E.C. A phase II study of dihydroxyanthracenedione (DHAD, Mitoxantrone, NSC 301739) in advanced malignant melanoma. Invest New Drugs 4, 53–56 (1986). https://doi.org/10.1007/BF00172017
Issue Date:
DOI: https://doi.org/10.1007/BF00172017